Updated efficacy of mutant‑selective PI3Kα inhibitor RLY‑2608 in combination with fulvestrant in patients with PIK3CA‑mutant HR+/HER2- advanced breast cancer: ReDiscover trial
Download
Publications
RLY-2608, A First-in-class Mutant-selective PI3Kα Inhibitor, Suppresses Aberrant PI3Kα Signaling and Induces Lesion Regressions in an In Vivo Experimental Model of PIK3CA-related Vascular Malformations
Download
Efficacy of RLY-2608, a mutant-selective PI3Kα inhibitor in patients with PIK3CA-mutant HR+/HER2− advanced breast cancer: ReDiscover trial
Download
Poster: Tumor-agnostic efficacy and safety of lirafugratinib, a highly selective FGFR2 inhibitor, in patients with advanced solid tumors with FGFR2 fusions or rearrangements: the ReFocus study
Download
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2
Download
Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Ka inhibitor that decouples anti-tumor activity from hyperinsulinemia
Download
Oral Presentation: Clinical activity of lirafugratinib (RLY-4008), a highly selective FGFR2 inhibitor, in patients with advanced FGFR2-altered solid tumors: the ReFocus study
Download
Poster: Clinical activity of lirafugratinib (RLY-4008), a highly selective FGFR2 inhibitor, in patients with advanced FGFR2-altered solid tumors: the ReFocus study
Download
Updated Dose Escalation Results for ReFocus: A First-In-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Cholangiocarcinoma and Other Solid Tumors
Download
RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
Download
Pan-mutant and isoform selective PI3K⍺ inhibitor, RLY-2608, demonstrates selective targeting in a first-in-human study of PIK3CA-mutant solid tumor patients: ReDiscover trial
Download
A food effect and esomeprazole drug–drug interaction study of RLY-4008, a highly selective FGFR2 inhibitor, in healthy subjects
Download
First-in-human global multi-center study of RLY-2608, a pan mutant and isoform selective PI3Kα inhibitor, as a single agent in advanced solid tumor patients and in combination with fulvestrant in patients with advanced breast cancer
Download
ReFocus: A Phase 1/2 study of the highly selective FGFR2 inhibitor RLY-4008 in patients with advanced solid tumors, including breast cancer
Download
Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma patients using a novel cfDNA algorithm for treatment with RLY-4008, a highly selective irreversible FGFR2 inhibitor
Download
Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients with an FGFR2 fusion or rearrangement, FGFR inhibitor-naïve cholangiocarcinoma: ReFocus trial
Download
Discovery and Characterization of the Potent, Allosteric SHP2 inhibitor GDC-1971 for the Treatment of RTK/RAS Driven Tumors
Download
RLY-2608: the first allosteric mutant- and isoform-selective inhibitor of PI3Kα, is efficacious as a single agent and drives regressions in combination with standard of care therapies in PIK3CA mutant breast cancer models
Download
First Results of RLY-4008, a Potent and Highly Selective FGFR2 Inhibitor in a First-in-Human Study in Patients with FGFR2-Altered Cholangiocarcinoma and Multiple Solid Tumors
Download
Discovery and characterization of RLY-2608, the first allosteric, mutant, and isoform-selective inhibitor of PI3Kα
Download
First-in-human study of the highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors
Download
RLY‑4008, a Novel Precision Therapy for FGFR2‑Driven Cancers Designed to Potently and Selectively Inhibit FGFR2 and FGFR2 Resistance Mutations
Download